France Redefines Diagnostic Reimbursement with the First AI-Enabled and Genomic Tests Under RIHN 2.0
France has entered a new era of evidence-based reimbursement for diagnostic innovation.
On 5 June 2025, the Haute Autorité de Santé (HAS) issued its first formal decision under the renewed RIHN 2.0 framework, granting conditional reimbursement to VisioCyt® Bladder, an AI-assisted urine-cytology test developed by Vitadx for monitoring recurrence in non-muscle-invasive bladder cancer (NMIBC).
A few months later, on 25 September 2025, HAS delivered Opinion n° 2025.0046/AC/SEAP, approving conditional funding for NOVAGRAY RILA Breast®, a genomic assay predicting individual radiosensitivity in breast-cancer patients.
Together, these two rulings inaugurate France’s RIHN 2.0 “evidence-for-access” model, demonstrating that public reimbursement is now tied to prospective, HAS-approved real-world evidence (RWE). They confirm France’s leadership in performance-based, outcome-linked reimbursement for diagnostics spanning both artificial intelligence and genomics.
Key Highlights
- Two landmark approvals:
- VisioCyt Bladder (Vitadx) AI-assisted urine cytology for NMIBC surveillance (5 June 2025).
- NOVAGRAY RILA Breast (Novagray) genomic radiosensitivity test for personalised oncology (25 Sept 2025).
- First conditional reimbursements under RIHN 2.0, each linked to mandatory French RWE protocols.
- CE marking is no longer sufficient; market access now depends on nationally generated evidence.
- Alignment with the EU AI Act (2024) and HTA Regulation (2021/2282), positioning France as Europe’s reference state for adaptive, evidence-driven reimbursement.
Understanding RIHN 2.0: France’s Conditional Reimbursement Pathway for Innovative Diagnostics
RIHN 2.0 (Référentiel des Innovations Hors Nomenclature) is France’s new structured pathway for early reimbursement of in-vitro diagnostics (IVDs), particularly AI-driven or data-enabled tests not yet listed in the NABM (Nomenclature des Actes de Biologie Médicale).
It provides temporary “prise en charge dérogatoire” funding while real-world evidence (RWE) is collected under an HAS-approved protocol, bridging the gap between CE-mark regulatory approval and permanent national reimbursement.
🔹 Core Features of RIHN 2.0
- Conditional reimbursement: Temporary public coverage granted for innovative IVDs not yet in the NABM catalogue.
- Mandatory RWE protocol: Each application must include a prospective, HAS-approved study defining comparators, endpoints, sample size, and data-sharing commitments.
- Structured transition: Once clinical and medico-economic benefit is demonstrated, the technology may progress to full NABM listing.
- National governance: Joint oversight by HAS, DGOS, and CNAM ensures alignment between evidence, cost, and health-system priorities.
These features formalise a learning-through-evidence model where reimbursement depends on measurable performance in French clinical practice.
Scientific and Economic Foundation
The VISIOCYT-1 multicentre French trial (391 patients) achieved 80.9% overall sensitivity and 93.7% sensitivity for high-grade tumours, confirming major diagnostic gains over conventional cytology.
The follow-on RWE protocol approved under RIHN 2.0 Opinion n° 2025.0027 will now quantify avoided cystoscopies (€400–€600 each), workflow efficiencies, and downstream cancer-care savings.
Similarly, the NOVAGRAY RILA Breast® assay (Opinion n° 2025.0046) demonstrates how genomic diagnostics can access temporary funding while generating prospective outcome data.
Regulatory and Policy Significance
RIHN 2.0 institutionalises evidence-first reimbursement, complementing Forfait Innovation and Article 51 pilots.
HAS’s updated evaluation grid introduces explicit criteria for machine-learning algorithms, demanding transparency on algorithmic function, data governance, and clinical utility.
This approach aligns with EU frameworks, including the AI Act (2024) and HTA Regulation (2021/2282), which link reimbursement to demonstrable diagnostic value, algorithmic integrity, and system impact.
Strategic Implications
| Stakeholder | Implication |
| Developers | CE marking alone is insufficient. Success requires a robust, HAS-approved RWE design and generation of French data demonstrating clinical and economic benefit. |
| Payers & Policymakers | RIHN 2.0 offers a transparent governance model balancing innovation with accountability through performance-linked funding. |
| EU Landscape | Positions France as a reference state for adaptive, outcome-based reimbursement of AI and digital diagnostics and an operational model for future European HTA convergence. |
In essence
RIHN 2.0 transforms real-world evidence from a regulatory checkbox into a reimbursement instrument, marking France’s transition to a continuously learning, evidence-driven healthcare system.
France’s Evidence Revolution: HAS Opens the RIHN 2.0 Era for AI and Genomic Diagnostics
1 | From Evaluation to Implementation: France’s First Conditional Reimbursement for AI Diagnostics
On 5 June 2025, the Haute Autorité de Santé (HAS) issued Opinion n° 2025.0027/AC/SEAP, granting conditional reimbursement to VisioCyt Bladder, an AI-assisted urine-cytology test developed by Vitadx for surveillance of non-muscle-invasive bladder cancer (NMIBC).
This landmark ruling, the first under the renewed RIHN 2.0 framework, formally embeds artificial intelligence (AI) within France’s national health insurance reimbursement system.
A few months later, on 25 September 2025, HAS issued Opinion n° 2025.0046/AC/SEAP approving NOVAGRAY RILA Breast®, a genomic assay that predicts individual radiosensitivity in breast-cancer patients.
Together, these two decisions inaugurate a new evidence-linked reimbursement paradigm, confirming that real-world evidence (RWE) generation rather than regulatory approval alone is now the entry ticket to public funding.
2 | Understanding RIHN 2.0: France’s Conditional-Funding Framework for Innovative IVDs
RIHN 2.0 (Référentiel des Innovations Hors Nomenclature) provides France’s first structured route to temporary reimbursement for diagnostics not yet listed in the NABM (Nomenclature des Actes de Biologie Médicale).
It bridges the gap between CE-mark approval and permanent inclusion in the NABM by granting time-limited, conditional coverage while manufacturers generate French RWE under HAS oversight.
Key Features
- Temporary “prise en charge dérogatoire” funding tied to a mandatory HAS-approved RWE protocol.
- Defined transition pathway toward permanent NABM listing once clinical and medico-economic value is proven.
- Joint governance by HAS, DGOS (Direction Générale de l’Offre de Soins), and CNAM (Caisse Nationale d’Assurance Maladie).
- Digital submission via the SESAME portal, ensuring secure dossier tracking and reviewer interaction.
Application Requirements (SEO keywords: RIHN 2.0 application France HAS SESAME)
Every submission must follow the five-part HAS template:
- Eligibility arguments demonstrating novelty and lack of existing funding.
- Technical and clinical dossier with preliminary evidence.
- Full RWE protocol specifying comparators, endpoints, timelines, and GDPR/HDS compliance.
- The budget impact estimate was validated with DGOS and CNAM.
- Commitment to data disclosure and open results.
Scientific and Economic Interpretation: Evidence, Efficiency, and Economic Logic
Scientific Interpretation
The VISIOCYT-1 results confirm that AI-driven pattern-recognition algorithms can improve diagnostic sensitivity, reproducibility, and standardisation in urine cytology, particularly for high-grade urothelial carcinoma, where timely intervention determines long-term survival.
By reducing false-negative results, the test addresses one of the fundamental limitations of conventional cytology and enables a risk-adapted surveillance strategy consistent with French clinical guidelines (AFU – Association Française d’Urologie).
This outcome directly aligns with HAS’s dual evaluation objectives:
- measurable patient-level benefit (improved detection, earlier treatment), and
- system-level efficiency (reduced resource burden and avoidable procedures).
Economic and Workflow Implications
The economic rationale for inclusion under RIHN 2.0 rests on measurable savings and operational gains within the French health system:
| Mechanism of Value Creation | Economic/Operational Impact | Indicative Metric |
| Earlier detection of recurrence | Avoidance of late-stage interventions and hospitalisations | Cost avoidance per advanced NMIBC episode (€8 000–€12 000) |
| Reduced cystoscopy frequency | Direct savings on diagnostic procedures | Each avoided cystoscopy: €400–€600 |
| AI-assisted reporting | Standardisation, shorter turnaround, lower re-read rate | 20–30 % gain in cytopathology throughput |
| Optimised workforce use | Addresses shortage of trained cytopathologists | Productivity increase per FTE > 15 % |
Collectively, these effects underpin the cost-utility argument for eventual NABM integration.
Real-world data from the ongoing HAS-approved study will validate these hypotheses, providing quantitative inputs for a Budget Impact Analysis (BIA) and supporting long-term tariff setting under CNAM oversight.
6 | Economic and System Value: Turning Real-World Evidence into Measurable Impact
The RIHN 2.0 decision acknowledges that economic stewardship is inseparable from innovation funding. France’s model explicitly couples conditional reimbursement with economic accountability, positioning RWE as the bridge between innovation and value-based payment.
Key Economic Pillars
- Avoided low-value procedures → direct cost savings to CNAM.
- Improved clinical precision → fewer missed high-grade recurrences and complications.
- Optimised laboratory efficiency → AI-assisted standardisation and reduced turnaround times.
- Preventive economic return → earlier intervention lowers downstream oncology and hospital costs.
Under RIHN 2.0, these savings are no longer theoretical; they are tracked through the approved RWE protocol, with predefined endpoints on cost, utilisation, and clinical outcome.
Successful demonstration of economic benefit is now the decisive criterion for transition from temporary to permanent reimbursement in the NABM.
7 | HAS Evaluation Framework for AI Diagnostics Transparency, Governance, and Economic Value
France has formally integrated artificial intelligence (AI) into its health technology assessment (HTA) ecosystem.
Under RIHN 2.0, the Haute Autorité de Santé (HAS) applies a dedicated evaluation grid for AI-based in-vitro diagnostics (IVDs) and digital pathology tools, marking the first time algorithmic transparency, data governance, and economic performance have become explicit regulatory criteria for reimbursement.
Four Assessment Dimensions (HAS, 2024 Update)
| Criterion | HAS Expectation | Keywords |
| Algorithmic transparency | Full disclosure of the algorithm’s clinical purpose, training data, validation methods, and update policy. | AI diagnostics France, algorithm validation, CE-marked software |
| Data governance & ethics | GDPR and HDS compliance, CNIL registration, and dataset representativeness across French populations to prevent bias. | GDPR France, health-data governance, ethical AI |
| Clinical and analytical utility | Demonstrated diagnostic improvement, reproducibility, and time-to-result gains over the NABM standard of care. | RWE France, diagnostic accuracy, HAS protocol |
| Economic and organisational value | Preliminary cost-utility or budget-impact analysis showing health-system efficiencies and sustainability. | cost-effectiveness France, health economics, BIA |
The “Learning-Through-Evidence” Model
RIHN 2.0 transforms reimbursement from a static list into a dynamic evidence cycle.
Each AI diagnostic is funded conditionally, with post-market data continuously feeding back into HAS evaluation. Technologies demonstrating sustained accuracy, safety, and cost-effectiveness are rewarded with permanent NABM integration and potential tariff adjustment.
This adaptive framework mirrors the EU AI Act (2024) and HTA Regulation (2021/2282), positioning France as the reference state for performance-based reimbursement in Europe.
Funding typically lasts three years, is renewable once, and is financed directly through CNAM. At completion, HAS reviews the RWE results to decide between permanent NABM inclusion, extension, or termination.
3 | Defining Innovation: How HAS Evaluates RIHN 2.0 Applications
Under Article R.165-63 of the French Social Security Code, HAS determines whether a diagnostic is “innovative”. Four dimensions guide this appraisal:
| Dimension | HAS Expectation | Typical Evidence |
| Technological or Methodological Novelty | Demonstrable algorithmic or analytical advance (AI automation, new biomarker, digital workflow). | Bench validation, AI training set description. |
| Stage of Diffusion | Early market stage; not yet in NABM/CCAM. | Diffusion data, pricing context. |
| Patient Safety | Analytical validity and risk management per ISO 14971 and IVDR. | CE certificate, traceability records. |
| Clinical & Economic Benefit | Demonstrable improvement in accuracy, workflow, or resource use. | Pilot data modelled cost offsets. |
All applicants must include a prospective, comparative, ethically compliant RWE study typically ≤ 36 months aligned with GDPR, CNIL, and HDS standards.
Outcomes: HAS may issue (1) favourable with conditions, (2) favourable pending clarification, or (3) unfavourable opinions, each published and shared with DGOS and CNAM for activation.
4 | Case Study: VisioCyt Bladder and NOVAGRAY RILA Breast Under RIHN 2.0
VisioCyt Bladder (AI urine cytology)
Developed by Vitadx, VisioCyt Bladder uses machine-learning algorithms to analyse digital urine-cytology slides, identifying urothelial carcinoma cells in patients with NMIBC.
Its goal: reduce the need for repeated cystoscopies, each costing €400–€600, while improving sensitivity and patient comfort.
- HAS Opinion n° 2025.0027/AC/SEAP (5 June 2025) is the first AI-driven IVD to receive conditional funding under RIHN 2.0.
- RWE Protocol: Multicentre French study measuring diagnostic accuracy, workflow impact, and economic savings.
- Clinical Benefit: Enhanced detection of recurrence and earlier intervention aligned with AFU guidelines.
- Economic Rationale: Avoided procedures and standardised laboratory workflows drive system-level savings.
NOVAGRAY RILA Breast (genomic radiosensitivity assay)
Developed by Novagray (SAS), RILA Breast® quantifies individual radiosensitivity to predict toxicity risk and optimise radiotherapy planning.
- HAS Opinion n° 2025.0046/AC/SEAP (25 September 2025) conditional reimbursement under the same legal basis (L.162-1-24 CSS).
- RWE Protocol: French prospective registry to assess correlation between RILA score, clinical outcomes, and resource use.
- Policy Relevance: Shows RIHN 2.0 applicability beyond AI, extending to personalised genomic testing and precision oncology.
Together, VisioCyt and RILA Breast illustrate how France is operationalising performance-based reimbursement for next-generation diagnostics across AI and genomics.
5 | Clinical Evidence and Health-Economic Performance
VISIOCYT-1 Trial: Diagnostic Accuracy in Real Life
| Metric | Result (VisioCyt) | HAS Reference / Comment |
| Sensitivity – overall | 80.9% | > 70 % target met clinically meaningful gain. |
| Specificity | 61.8% | Slightly below the nominal 75% benchmark, but acceptable exploratory variance. |
| Sensitivity – high-grade tumours | 93.7% | Strong performance for progression prevention. |
| Sensitivity – low-grade tumours | 66.7% | Substantial improvement over legacy cytology (≤ 40 %). |
A validation cohort (85% overall sensitivity; 93% high-grade; 77% low-grade) confirmed robustness. These results support HAS’s goal of reducing false negatives and improving workflow efficiency.
Health-Economic Implications
- Direct cost avoidance: Fewer cystoscopies (€400–€600 each) and reduced pathology lab burden.
- Indirect savings: Earlier detection prevents progression to cost-intensive therapy.
- Operational impact: AI-assisted cytology standardises reports and accelerates turnaround times.
For Novagray RILA Breast, economic value will be quantified through reduced toxicity management costs and optimised radiotherapy resource allocation.
RIHN 2.0 has converted real-world evidence into a currency for reimbursement, enabling France to fund innovation while it learns.
By backing both AI-powered urine cytology (VisioCyt) and genomic radiosensitivity testing (RILA Breast), France demonstrates that its health-economic model can support precision diagnostics across domains, anchoring the country as Europe’s reference state for evidence-linked access.
8 | HAS Evaluation Framework for AI Diagnostics: Transparency, Performance, and Real-World Accountability
France has now embedded artificial intelligence (AI) directly into its health technology assessment (HTA) and reimbursement framework through the renewed RIHN 2.0 pathway.
For the first time, algorithmic transparency, data governance, clinical utility, and economic value are mandatory criteria for conditional reimbursement of AI-enabled in vitro diagnostics (IVDs) and digital pathology tools.
This reflects France’s strategic commitment to “evidence-linked innovation”, a model in which technologies are rewarded not for potential, but for demonstrated real-world performance within the national health system.
Key Assessment Criteria for AI Diagnostics under RIHN 2.0
Applicants submitting AI-enabled diagnostics must provide comprehensive, verifiable evidence across four mandatory dimensions, as defined in the HAS submission guide
(Soumission d’une demande de prise en charge dérogatoire – 2024 update).
| Criterion | What HAS Expects (Updated for 2025) |
| 1. Algorithmic role and functionality |
A complete and technically auditable description of the algorithm, including: • The exact clinical purpose (diagnosis, triage, prognostic stratification, workflow support). • Input data types, feature extraction, model architecture, and decision logic. • Full traceability of model training: dataset origin, representativeness, pre-processing, and exclusion criteria. • Independent validation on French or EU clinical datasets. • A documented lifecycle-management process covering version control, performance drift monitoring, retraining triggers, and safety updates. Reference: HAS – Évaluation des dispositifs médicaux numériques https://www.has-sante.fr/jcms/p_3287486/fr/evaluation-des-dispositifs-medicaux-numeriques |
| 2. Data governance and integrity |
The solution must demonstrate strict compliance with: • GDPR – lawful basis, minimisation, and explicit purposes for health data: https://eur-lex.europa.eu/eli/reg/2016/679/oj • CNIL guidance on AI and health-data processing, including DPIA (AIPD) requirements: https://www.cnil.fr/fr/intelligence-artificielle • HDS Certification (Hébergeur de Données de Santé) for storage/hosting: https://esante.gouv.fr/securite/hebergeurs-de-donnees-de-sante-hds HAS expects traceable documentation of data lineage, representativeness of French patient populations, governance processes addressing algorithmic bias, and cybersecurity documentation aligned with ANS (Agence du Numérique en Santé) guidelines. |
| 3. Clinical and analytical utility |
Evidence must show that the AI adds measurable value compared with the NABM (Nomenclature des actes de biologie médicale) standard:
https://www.legifrance.gouv.fr/codes/id/LEGITEXT000006072665 Requirements include: • Demonstration of diagnostic or prognostic improvement: sensitivity, specificity, PPV, NPV. • Comparison with SOC (standard of care) workflows used in France. • Reduction in time-to-result or clinical decision-making latency. • Prospective or retrospective studies in multicentre French or EU settings. • Real-world evidence consistent with HAS methodological expectations. Reference: HAS – Méthodes d’évaluation clinique et RWE https://www.has-sante.fr/jcms/c_2830257/fr/real-world-evidence-rwe |
| 4. Economic and organisational relevance |
HAS requires early economic evaluation anchored in French payer expectations, including: • A Budget Impact Analysis (BIA) compatible with CNAM templates: https://www.ameli.fr/ • Preliminary Cost-Utility Analysis (CUA) when relevant, referencing QALYs and French cost conventions. • Demonstration of resource efficiencies: reduced LOS, fewer unnecessary tests, avoided admissions, improved workflow throughput. • Alignment with DGOS organ |
Each submission must demonstrate traceability from data to decision, showing precisely how algorithmic output leads to a validated clinical consequence.
This principle of “data–decision traceability” sits at the core of HAS’s new AI governance model and is likely to become a benchmark across Europe.
Evaluation Principles and European Policy Alignment
HAS’s AI evaluation grid is synchronised with emerging European frameworks, ensuring that national reimbursement policy supports cross-border regulatory convergence:
- The EU AI Act (2024) establishes risk-based classification for “high-risk medical AI,” mandating algorithmic explainability, human oversight, and post-market monitoring.
- IVDR (Regulation EU 2017/746) reinforces analytical and clinical validation for software-as-a-medical-device (SaMD) and machine-learning-based IVDs.
- EUnetHTA 21 / EU HTA Regulation (2021/2282) promotes real-world evidence (RWE) and dynamic assessment cycles, harmonising outcome-based evaluations across Member States.
By embedding these principles into RIHN 2.0, France positions itself as the European reference state for AI-ready reimbursement, combining ethical, technical, clinical, and economic criteria within a single assessment continuum.
The “Learning-Through-Evidence” Paradigm
Unlike traditional reimbursement catalogues such as the NABM or LPPR, RIHN 2.0 treats every AI diagnostic as part of a continuous learning system.
Data generated in real-world clinical use feeds back into HAS’s post-market performance monitoring, ensuring that coverage decisions remain dynamic, evidence-led, and accountable.
This adaptive reimbursement model rewards technologies that improve with experience, a critical advance for machine-learning systems whose predictive accuracy evolves with dataset size and diversity.
In practice, this means that AI diagnostics in France are judged not only by their design architecture, but by their behavioural performance in real-world clinical workflows:
- Reproducibility across sites (multicentre robustness),
- Algorithmic stability (resistance to drift and bias),
- Operational impact (workflow efficiency, turnaround time), and
- Safety in diverse care settings.
Such performance-based reimbursement echoes broader trends across Europe toward value-based healthcare, where RWE = currency of access.
Why It Matters
RIHN 2.0’s AI evaluation framework transforms post-market evidence into an instrument of pricing, policy, and patient protection.
For developers, it introduces clear regulatory expectations and accelerates early market entry through evidence-linked funding.
For payers, it ensures that public investment follows performance, not promises.
And for the EU, it offers a living model of how reimbursement, ethics, and innovation can coexist in the age of artificial intelligence.
8 | Integrating RIHN 2.0 Within France’s Innovation & Reimbursement Ecosystem
France’s multi-pathway model for funding health innovation
RIHN 2.0 is one part of a cohesive reimbursement continuum that aligns innovation funding → evidence generation → permanent listing. In concert with Forfait Innovation, Article 51 experiments, and PECAN, it enables a predictable route from pilot to tariff.
1) Forfait Innovation: evidence-linked early funding for devices/procedures
- Legal basis: Art. L.165-1-1 CSS.
- Purpose: Early reimbursement (typically 2–4 years) for high-risk devices, procedures, or hybrid tech with strong promise but incomplete evidence.
- Core mechanics: HAS-approved protocol; medico-economic evaluation under HAS/DGOS; exit to LPPR/CCAM when benefit proven.
- RIHN 2.0 parallel: Applies the same “fund-while-learning” logic to IVDs (including AI-enabled laboratory tools), with exit to NABM.
2) Article 51 real-world payment & pathway experiments
- Legal basis: LFSS 2018, art. 51.
- Focus: Alternative payments (bundles, outcomes-based models) and new care pathways.
- How it helps diagnostics/AI:
- Bundle diagnostics inside episode-based payments.
- Trial value-based purchasing tied to outcome metrics.
- Enable regional oncology/chronic-care integration for tests proven under RIHN.
3) PECAN: the digital fast-track (connected care & telemonitoring)
- Scope: Digital therapeutics, telemonitoring, decision support, and app-device ecosystems.
- What it does:
- Runs real-world pilots integrated with Ségur du Numérique and Mon Espace Santé.
- Supports transitional funding (e.g., L.162-52) once interoperability and clinical impact are demonstrated.
- Bridge to diagnostics: AI diagnostics (e.g., VisioCyt) can connect to telepathology/remote-reporting workflows validated via PECAN.
4) The pipeline at a glance
| Stage | Policy Instrument | Primary Focus | Funding Logic | Outcome |
| Pilot | PECAN / Article 51 | Digital & organisational innovation | Experimental/regional | Feasibility data |
| Conditional reimbursement | RIHN 2.0 / Forfait Innovation | IVDs, AI diagnostics, devices | Temporary funding tied to RWE | Evidence generation |
| Permanent listing | NABM / LPPR / CCAM | National catalogues | Full tariff integration | Routine adoption |
Strategic implications (SEO: RIHN 2.0 France, Forfait Innovation, Article 51, PECAN, market access France)
- Clear entry lanes: Earlier funding if you accept RWE commitments and French-format dossiers.
- Continuity of coverage: Avoids “evidence gap” shocks between pilot and national tariff.
- EU relevance: Operationalises RWE and performance-based reimbursement consistent with HTA Regulation (2021/2282) and the EU AI Act (2024).
9 | France as Europe’s Test-bed for Evidence-Based AI Reimbursement
From policy theory to operational reality
With RIHN 2.0, France has implemented what EU policy has envisioned: reimbursement that is earned by prospective real-world evidence instead of pre-market assertions.
The Kirchhoff et al. (2025) “AI Score” as a valuation lens
A structured model for valuing diagnostic AI by data complexity, disease complexity, clinical-question complexity, and degree of AI involvement provides an economic logic for scaled recognition.
| Dimension | AI Score (Kirchhoff) | RIHN 2.0 / HAS analogue |
| Data & evidence maturity | Dataset diversity, bias control | French RWE, cohort representativeness, bias mitigation |
| Disease complexity | Heterogeneity/diagnostic difficulty | Unmet need & clinical-impact rationale |
| Clinical role | Support vs. replace | Declared algorithmic role and oversight |
| Accountability | Shared responsibility | Transparency, governance, update policy |
| Economic link | Value-based scaling | Conditional funding tied to demonstrated utility |
Why this matters: France is the first in the EU to translate this valuation logic into funding practice, using RWE, governance, and clinical utility as triggers for tariff decisions.
Strategic implications across Europe
- Explainability & oversight: Aligned with the EU AI Act “high-risk” provisions; sets a de facto standard for Member States.
- HTA convergence: RWE-based reimbursement aligns with Joint Clinical Assessment (JCA) expectations.
- Procurement template: Reinforces value-based procurement within NABM/LPPR/CCAM coding ecosystems.
10 | Strategic Guidance for Innovators: How to Win Under RIHN 2.0
Rule #1: RWE is the product. CE marking opens the door; French real-world evidence gets you paid.
1) Design RWE as a core asset (not a post-market chore)
- Start before CE completion; pre-agree endpoints with HAS (early dialogue).
- Use multicentre, pragmatic designs across GHT/CHU networks; power for accuracy and system impact.
- Endpoints aligned to HAS/NABM: sensitivity/specificity, PPV/NPV, time-to-result, avoided procedures, LOS, pathway fit.
Keywords: real-world evidence, France, HAS RWE protocol, diagnostic accuracy, pragmatic study design.
2) Make the dossier French and NABM-literate
- Build to the RIHN template (Parts I–III); use NABM taxonomy to describe acts.
- Provide DGOS/CNAM-style budget and utilisation models that can be lifted into tariff work.
Keywords: NABM reimbursement France, HAS dossier, RIHN 2.0 process.
3) Engineer data governance by design
- HDS-certified hosting, CNIL registration, explicit consent and audit trails.
- Pre-write your AIPD and maintain version control for the algorithm.
Keywords: GDPR compliance France, HDS certification, CNIL registration, AI data governance.
4) Frame evidence in system-level value terms
- Quantify avoided procedures (e.g., cystoscopy €400–€600), throughput gains, and toxicity/resource savings (for genomics).
- Deliver BIA + cost-utility scenarios with French cost inputs; map to service attendu.
Keywords: health-economic modelling France, value-based diagnostics, service attendu HAS.
5) Work iteratively with the ecosystem
- HAS early advice; ARS/GHT/CHU for sites; DGOS/CNAM for budget logic.
- Consider Forfait Innovation / Article 51 if your solution touches procedures or pathways.
Outcome to target: RIHN success → NABM listing (or LPPR/CCAM, if relevant) with a tariff justified by observed French RWE.
11 | Why this matters beyond France
France now offers a repeatable, evidence-linked route to reimbursement for AI and genomic diagnostics. It gives innovators clarity, payers assurance, and patients earlier access, turning RWE into the currency of market access.
“RIHN 2.0 transforms reimbursement from a static list into a living contract between innovation, evidence, and the healthcare system.”
References
🇫🇷 Core RIHN 2.0 / HAS Sources
- HAS—RIHN 2.0: Guide de dépôt de dossier (v.2024)—official template (Parts I–V) and methodological standards.
- HAS — Déposer une demande au RIHN 2.0 — eligibility, evidence criteria, and submission procedure.
- HAS SESAME portal — secure submission and tracking environment.
- HAS Opinion n° 2025.0027 — VisioCyt® Bladder (5 Jun 2025) — first AI-enabled IVD approved for conditional reimbursement.
- HAS Opinion n° 2025.0046 — NOVAGRAY RILA Breast® (25 Sep 2025) — genomic radiosensitivity assay under RIHN 2.0.
Complementary French Instruments
- Ministère de la Santé — Forfait Innovation — early-access funding for medical devices/procedures.
- Legifrance—LFSS 2018, Article 51—legal basis for experimental payment models.
- DREES — Évaluation des expérimentations Article 51 — evaluation methodology and objectives (2023 update).
Reimbursement & Nomenclature
- Ameli — NABM — reimbursable laboratory acts.
- Ameli — CCAM — procedural catalogue for hospital/outpatient coding.
- Ameli — LPPR — reimbursable medical devices and products.
Data Governance & Ethics
- CNIL — Guide Santé (RGPD) — GDPR compliance in healthcare.
- ANS — Hébergeurs de Données de Santé (HDS) — registry of certified health-data hosts.
- Health Data Hub — Documentation SNDS (LPP/NABM) — data-use and linkage guidelines.
🇪🇺 European Frameworks
- EU AI Act (2024) — transparency and oversight for high-risk medical AI.
- Regulation (EU) 2017/746 — IVDR — analytical and clinical-performance standards.
- EU HTA Regulation (2021/2282) — joint clinical assessment methodology across Member States.
Last updated: November 2025
Glossary of Key Terms
Service Attendu (SA): Expected clinical/public-health benefit guiding HAS reimbursement decisions. Keywords: service attendu HAS.
AI Diagnostic (Diagnostic fondé sur l’IA): In vitro or software-as-medical-device using machine learning for data analysis; assessed by HAS for transparency and clinical utility. Keywords: AI diagnostics France, digital pathology.
Article 51 (LFSS 2018): Framework for experimental payment and care pathways enabling bundled or value-based reimbursement. Keywords: Article 51 France, value-based healthcare.
ARS (Agences Régionales de Santé): Regional health agencies coordinating innovation pilots and data collection sites. Keywords: ARS France, innovation pilot health.
CCAM: National catalogue of medical procedures; basis for coding and cost weighting. Keywords: CCAM codes France.
CNAM: National Health Insurance Fund integrating RIHN 2.0 and Forfait Innovation budgets. Keywords: CNAM reimbursement, France.
CNEDiMTS: The HAS committee for devices/IVDs evaluates RWE protocols and issues opinions. Keywords: HAS device evaluation.
CNIL / RGPD (GDPR): French data authority / EU privacy law ensuring consent, DPIA, and lawful processing. Keywords: GDPR, health data, France.
HDS: “Hébergeur de Données de Santé”; certification required for compliant data hosting. Keywords: HDS certification France.
HTA (Health Technology Assessment): Evaluation of medical, economic, and ethical dimensions guiding reimbursement. Keywords: HTA, France, EU, JCA.
IVD / IVDR: In vitro diagnostic device regulated under IVDR (EU 2017/746). Keywords: IVDR compliance, France.
LPPR / LPP: Reimbursable devices catalogue (post-Forfait Innovation integration). Keywords: LPPR France reimbursement.
Mon Espace Santé / Ségur du Numérique: National EHR infrastructure enabling interoperability and telemonitoring. Keywords: digital health, France, EHR.
NABM: Laboratory acts nomenclature; end-state for permanent reimbursement. Keywords: NABM listing France.
PECAN: Digital-health fast-track for telemonitoring / DTx / AI-assisted care. Keywords: PECAN, France, digital health.
RIHN 2.0: Conditional reimbursement for innovative IVDs linked to an HAS-approved RWE study. Keywords: RIHN 2.0 France reimbursement.
RWE (Données en vie réelle): Evidence from clinical practice on safety, performance, and economic impact; required for RIHN 2.0. Keywords: RWE France diagnostics.